|
Date
of Proposal: April 7, 2008
Proposal
Number: PRN 2008-97
Proposal
Description: The proposal is to
amend N.J.A.C. 13:71-23.8 to authorize the
continuing use of aminocaproic acid (Amicar)
with Furosemide (Lasix) as an adjunct medication
to treat respiratory bleeding in standardbred
race horses that have been placed on the
Furosemide list. Because of uncertainty
regarding the effectiveness of AMICAR in
treating exercise-induced pulmonary hemorrhage,
the Racing Commission originally authorized
the use of AMICAR only until Dec. 31, 2007.
By doing so, the Commission hoped for the
development of scientific evidence either
supporting the medical use of AMICAR or
determining that its use is not recommended.
To date, however, no body of evidence has
materialized to establish AMICAR’s
therapeutic value or show that it causes
harmful side effects. In proposing the
current amendment to allow for continued
use of AMICAR, the Commission anticipates
that the racing industry’s experience
in using AMICAR in 2007 will generate meaningful
public
comment as to whether the drug’s use
in New Jersey has been a ositive or negative
experience.
The
public comment period will also allow interested
parties to submit research studies from
other jurisdictions that are published,
or otherwise recognized by the academic
community as completed. Following the 60-day
comment period, the Commission will evaluate
all available information and decide whether
to adopt a rule permanently authorizing
the use of AMICAR. The proposed amendment
appears in the April 7, 2008 edition of
the New Jersey Register.
Summary
of Proposal: A detailed summary
of the proposed rule is posted on the New
Jersey Racing Commission Web site at: www.njpublicsafety.org/racing/proposed.html
Public
Comment: Public comment on the
proposed rule will be accepted until June
6, 2008. Please direct all comments to:
Michael
Vukcevich, Deputy Director
New Jersey Racing Commission
Department of Law and Public Safety
P.O. Box 088, Trenton, New Jersey 08625-0088
# # # |
